Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bolin, K.
Right arrow Articles by Willers, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bolin, K.
Right arrow Articles by Willers, S.
(Chest. 2006;129:651-660.)
© 2006 American College of Chest Physicians

The Cost Utility of Bupropion in Smoking Cessation Health Programs*

Simulation Model Results for Sweden

Kristian Bolin, PhD; Björn Lindgren, PhD and Stefan Willers, MD, PhD

* From Lund University Centre for Health Economics (Drs. Bolin and Lindgren), Vårdal Institute, and Department of Health Sciences, Lund University; and Unit of Preventive Medicine (Dr. Willers), Heart and Lung Centre and Occupational and Environmental Medicine, Lund University Hospital, Lund, Sweden.

Correspondence to: Kristian Bolin, PhD, Lund University Centre for Health Economics, PO Box 705, SE-220 07 Lund, Sweden; e-mail: Kristian.Bolin{at}luche.lu.se

Abstract

Study objectives: To calculate incremental cost-utility ratios (cost per quality-adjusted life-year [QALY] gained) for bupropion (Zyban; GlaxoSmithKline; Gothenburg, Sweden), as compared to nicotine replacement therapy (NRT) in smoking cessation programs for a follow-up period of 20 years.

Design: The Global Health Outcomes simulation model was used for a male cohort and for a female cohort as a point of departure but was further extended in order to include the following: (1) the indirect effects of smoking cessation on production and consumption in the economy, and (2) morbidity-specific QALYs gained.

Setting: Sweden in 2001.

Patients or participants: Model cohort consisting of 612,851 male and 780,970 female smokers, distributed by age, ≥ 35 years old, as in the Swedish population of 2001.

Interventions: Bupropion, as compared to NRT (nicotine patches and nicotine gums), in smoking cessation programs for a follow-up period of 20 years.

Measurements and results: When the indirect effects on production and consumption were taken into account, bupropion was cost saving in comparison to both NRTs. When only the direct costs were included, bupropion was still cost saving in comparison to nicotine gum. The incremental costs per QALY gained were relatively low for bupropion in comparison to nicotine patches, 6,600 Swedish kronas (SEK) (approximately Formula 725) per QALY gained for men and 4,900 SEK (approximately Formula 535) for women, all calculations in 2001 Swedish prices. The comprehensive sensitivity analysis showed robust results; results were, however, more sensitive to quit rates and intervention costs than to other variables.

Conclusions: Bupropion is a cost-effective therapy in smoking cessation programs. Furthermore, recent studies report even higher effectiveness in terms of quit rates than was assumed here, indicating that our estimated cost-utility ratio should be even more favorable to bupropion.

Key Words: bupropion • economic evaluation • nicotine-replacement therapy • smoking cessation intervention • Sweden






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Chest Physicians.